Tech Company Financing Transactions
Scala Biodesign Funding Round
Scala Biodesign, based in Tel-Aviv, secured $5.5 million from TLV Partners.
Transaction Overview
Company Name
Announced On
9/11/2023
Transaction Type
Venture Equity
Amount
$5,500,000
Round
Seed
Investors
TLV Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Yosef Karo St. 18,
Tel-Aviv, 6701422
IL
Tel-Aviv, 6701422
IL
Phone
Undisclosed
Website
Email Address
Overview
Scala provides a unique one-shot computational solution to dramatically increase the value and accelerate the development of proteins into commercial products. We believe that nature holds solutions to some of the biggest challenges facing humanity. The pharmaceutical, chemical and sustainability industries are harnessing nature's molecular machines -- enzymes, antibodies, and other proteins -- to generate life-saving drugs and green manufacturing processes. But natural proteins lack the resilience and specificity that modern medicine and industry require.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ravit Netzer
Chief Technical Officer
Adi Goldenzweig
Browse more venture capital transactions:
Prev: 9/11/2023: Thirona venture capital transaction
Next: 9/11/2023: GHGSat venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs